Drug Profile
Finerenone - Bayer HealthCare Pharmaceuticals
Alternative Names: Kerendia; BAY-94-8862; KERENDIA; KerendiaLatest Information Update: 29 Mar 2024
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Class Amides; Antihyperglycaemics; Heart failure therapies; Naphthyridines; Nitriles; Small molecules; Urologics
- Mechanism of Action Mineralocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Diabetic nephropathies
- Phase III Chronic heart failure; Heart failure; Renal failure; Type 1 diabetes mellitus
Most Recent Events
- 26 Feb 2024 Phase-III clinical trials in Renal failure (Adjunctive treatment) in China (PO) (NCT05901831)
- 26 Feb 2024 Phase-III clinical trials in Type 1 diabetes mellitus (Adjunctive treatment) in United Kingdom, China (PO) (NCT05901831)
- 11 Nov 2023 Pharmacodynamics data from preclinical trial in Renal failure presented at the American Heart Association Scientific Sessions (AHA-2023)